EMD Biosciences, Inc. Releases The Inhibitor SourceBook, The First Comprehensive Guide To Inhibitors For Signal Transduction Research And Drug Discovery
10/19/2005 5:11:46 PM
EMD Biosciences, Inc. (EMD), a major supplier of premium research tools for proteomics and disease pathway analysis through its global brands Calbiochem(R), Novabiochem(R), and Novagen(R), today announced the release of the Calbiochem(R) Inhibitor SourceBook(TM). The first of its kind in the industry, this publication represents the most comprehensive listing of inhibitors for signal transduction and drug discovery research. EMD is part of the Life Science and Analytics (LSA) division of Merck KGaA (Darmstadt, Germany) and operates as EMD Biosciences, Inc. in North America and as Merck Biosciences outside North America.
comments powered by